

PERIODICAL ROOM
HEALTH SCIENCES LIBRARY

THE JOURNAL OF
CLINICAL
INVESTIGATION

LIBRARY
MAY 18 1981

PUBLISHED BY THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, INC.

MAY 1981 VOLUME 67 NUMBER 5

JCINAO 67(5) 1241-1592 (1981)

ISSN 0021-9738

9

THE JOURNAL OF CLINICAL INVESTIGATION

Produced by The Rockefeller University Press, New York, for
The American Society for Clinical Investigation, Inc.

PHILIP W. MAJERUS, *Editor*

Associate Editors

DAVID H. ALPERS
WILLIAM H. DAUGHADAY
SAULO KLAHR

STUART KORNFELD
CHARLES W. PARKER
BURTON E. SOBEL

The Editorial Committee of The American Society for Clinical Investigation, Inc.

ROBERT H. ALLEN, *Denver, Colo.*
THOMAS E. ANDREOLI, *Birmingham, Ala.*
CLAUDE D. ARNAUD, *San Francisco, Calif.*
BERNARD M. BABIOR, *Boston, Mass.*
ARTHUR BANK, *New York*
JOHN BAXTER, *San Francisco, Calif.*
BARRY M. BRENNER, *Boston, Mass.*
H. FRANKLIN BUNN, *Boston, Mass.*
RONALD G. CRYSTAL, *Bethesda, Md.*
ROBERT M. DONALDSON, JR., *New Haven, Conn.*
STEPHEN E. EPSTEIN, *Bethesda, Md.*
ANTHONY S. FAUCI, *Bethesda, Md.*
MICHAEL FIELD, *Chicago, Ill.*
MICHAEL M. FRANK, *Bethesda, Md.*
GERALD GLICK, *Chicago, Ill.*
ROBERT GLICKMAN, *New York*
JOSEPH L. GOLDSTEIN, *Dallas, Tex.*

JOSEPH C. GREENFIELD, *Durham, N. C.*
SCOTT M. GRUNDY, *San Diego, Calif.*
CARL R. KAHN, *Bethesda, Md.*
YUET WAI KAN, *San Francisco, Calif.*
FRANKLYN G. KNOX, *Rochester, Minn.*
NEIL A. KURTZMAN, *Chicago, Ill.*
ROBERT J. LEFKOWITZ, *Durham, N. C.*
PETER T. MACKLEM, *Montreal, Quebec*
GERALD L. MANDELL, *Charlottesville, Va.*
DAVID G. NATHAN, *Boston, Mass.*
JERROLD M. OLEFSKY, *Denver, Colo.*
JACK H. OPPENHEIMER, *Minneapolis, Minn.*
ALAN K. PIERCE, *Dallas, Tex.*
ARTHUR H. RUBENSTEIN, *Chicago, Ill.*
SHAUN RUDDY, *Richmond, Va.*
THOMAS W. SMITH, *Boston, Mass.*
JOHN D. STOBO, *San Francisco, Calif.*

THOMAS P. STOSSEL, *Boston, Mass.*

THE JOURNAL OF CLINICAL INVESTIGATION publishes original papers on research pertinent to human biology and disease. Work with animals or in vitro techniques is acceptable if it is relevant to human normal or abnormal biology. No substantial part of a paper may have been or may be published elsewhere. Single, complete papers are preferred to a series of interdependent ones.

It is assumed that all clinical investigation described in manuscripts submitted to this JOURNAL shall have been conducted according to the principles expressed in the Declaration of Helsinki, which has been endorsed by The American Society for Clinical Investigation, Inc. (see Vol. 46, p. 1140).

Manuscripts are published in the order of final acceptance after review and revision. Papers requiring much editing will be delayed until they are in good form. For information on preparation of manuscripts, see Instructions to Authors published in the January and July issues.

Submit manuscripts in three complete sets to:

Dr. Philip W. Majerus, Editor
THE JOURNAL OF CLINICAL INVESTIGATION
Editorial Office
Division of Hematology-Oncology
Washington University School of Medicine
St. Louis, Missouri 63110

Each manuscript submitted must be accompanied by a processing fee of \$30 in the form of a check or money order. In addition, the author of each paper accepted will be charged \$30 per published page.

Authors may purchase reprints at prices furnished with galley proof. Others desiring reprints should write the authors, not the JOURNAL. Claims for copies lost in the mails must be received within 30 days (domestic) or 90 days (foreign) of the date of issue. Changes of address must be received at least 2 weeks in advance of the date of issue.

Two volumes of six issues each appear annually. The rate for both foreign and domestic subscriptions is \$75 per year (postal surcharge Europe only, \$22 net), payable in advance. Medical students, interns, fellows, and residents of approved hospitals may subscribe at the special rate of \$37.50 per year (personal check only). Single copies are \$6.50 a copy. Remit by draft or check drawn on U. S. banks, or by postal money order, payable to THE JOURNAL OF CLINICAL INVESTIGATION, The Rockefeller University Press, P. O. Box 5108, Church Street Station, New York 10249. Claims for nonreceipt of issues will be honored when received within 3 months of mailing for U. S. A. subscribers, 6 months for foreign subscribers. For information on subscriptions and back copies write to Order Service, The Rockefeller University Press, 1230 York Ave., New York 10021. Subscriptions and back copies are available in *Microfiche* and *microfilm* through University Microfilms International, 300 North Zeeb Road, Dept. P.R., Ann Arbor, Mich.

Address correspondence about manuscripts in press to:

THE JOURNAL OF CLINICAL INVESTIGATION
Journals Office
1230 York Avenue
New York 10021

The appearance of the code at the bottom of the first page of an article in this journal indicates that the Publisher gives consent for individual copies of that article to be made for personal or internal use. This consent is given on the condition, however, that—for copying beyond the limited quantities permitted under Sections 107 or 108 of the U. S. Copyright Law—the copier pay the stated per-copy fee, for this journal \$1.00 per article, through the Copyright Clearance Center, Inc., 21 Congress Street, Salem, Massachusetts 01970, a nonprofit organization. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Copyright © 1981 The American Society for Clinical Investigation, Inc.

Network Theory in Autoimmunity

IN VITRO SUPPRESSION OF SERUM ANTI-DNA ANTIBODY BINDING TO DNA BY ANTI-IDIOTYPIC ANTIBODY IN SYSTEMIC LUPUS ERYTHEMATOSUS

NABIH I. ABDOU, HELEN WALL, HERBERT B. LINDSLEY, JOHN F. HALSEY, and TSUNEO SUZUKI, *Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, and Departments of Biochemistry and Microbiology, University of Kansas Medical Center, Kansas City, Kansas 66103; Veterans Administration Hospital, Kansas City, Missouri 64128*

ABSTRACT Regulation of serum anti-DNA antibody in systemic lupus erythematosus (SLE) by an antiidiotypic antibody was evaluated. Various sera from SLE patients in active and inactive states of their disease, as well as sera from normal individuals, were first completely depleted of anti-DNA and of DNA by affinity chromatography. The suppressive capacity of equimolar concentrations of the various depleted sera (blocking sera) on target lupus sera were determined. The target sera were from lupus patients with known DNA-binding capacity. Blocking sera from inactive SLE suppressed the binding of autologous anti-DNA antibody to [³H]DNA ($n = 19, P < 0.01$). Blocking sera from active SLE ($n = 19$), as well as human serum albumin, did not suppress. Sera from normal donors who had no contact with lupus patients or with lupus sera did not suppress ($n = 14, P > 0.5$), whereas those from normal donors who had contact with lupus patients or sera did suppress the binding ($n = 5, P < 0.02$). The anti-anti-DNA antibody suppressive activity in the inactive lupus serum was shown to be localized within the F(ab')₂ portion of immunoglobulin (Ig)G and could not be removed upon adsorption by normal human gammaglobulin. Furthermore, immune complexes could be detected by a Clq binding assay when the inactive lupus blocking sera were incubated with the anti-DNA antibody containing target sera. The

specificity of the suppressive serum factor was shown by its inability to block the binding of tetanus toxoid to antitetanus antibody and its ability to block the binding of DNA to F(ab')₂ fragments of active lupus IgG.

Regulation of serum anti-DNA antibody levels by anti-antibodies could induce and maintain disease remission in lupus patients and prevent disease expression in normals.

INTRODUCTION

Regulation of antibody synthesis and of lymphocytes involved in the immune response has been proposed by Jerne (1) to be controlled by a network of antibodies and lymphocytes. Antiidiotypic antibodies directed against cell-surface receptors or secreted idiotype molecules have been shown to be important elements in transplantation tolerance or the specific suppression of an antibody response (2, 3). Antiidiotypic antibodies that recognize and regulate the expression of idiotype determinants on the cell surface could theoretically play a key role in the induction of self-tolerance and the prevention of autoimmunity. Abnormalities in the idiotype antiidiotypic system could therefore lead to expression or expansion of autoreactive cell clones (4-6).

Self-tolerance is also dependent on suppressor cells (7). Suppressor cell dysfunction could in part be responsible for autoantibody production in systemic lupus erythematosus (SLE)¹ (8, 9). In fact, there appears to be a close interplay between suppressor cells and the idiotype network in the regulation of the immune response (10-12).

In this study we have tested an extension of the net-

¹Abbreviation used in this paper: SLE, systemic lupus erythematosus.

This work appeared in abstract form. (1980. *J. Allergy Clin. Immunol.* 65: 221; *Clin. Res.* 28: 338A.)

Address all correspondence to Dr. N. I. Abdou, University of Kansas Medical Center, Division of Allergy, Clinical Immunology and Rheumatology, Room 416C, Kansas City, Kans. 66103.

Received for publication 26 October 1980 and in revised form 24 November 1980.

work theory (1) with respect to modulation of the expression of autoantibody activity by presumed antiidiotypic factors. We have demonstrated the presence of autoantiidiotypic antibody in sera of inactive SLE patients. In normal individuals who have had contact with lupus material, we found a cross-reacting antiidiotypic antibody against double-stranded DNA antibody. The effector activity is present in the F(ab')₂ portion of immunoglobulin (Ig)G from sera of inactive SLE patients; it binds more avidly to autologous anti-DNA antibody than to antibody from unrelated donors. The blocking antibody could not inhibit an unrelated antigen-antibody reaction and could not be detected in sera of active SLE patients or in sera of normal individuals not exposed to lupus sera.

METHODS

Patients and controls. 19 patients who satisfied the American Rheumatism Association preliminary diagnostic criteria for SLE (13) were studied. 19 normal healthy individuals without personal or family history suggestive of an autoimmune state and with normal levels (<6.4% binding) of serum anti-DNA antibody were used as controls. 5 of the 19 normal individuals had contact with lupus patients and sera for varying periods of time (0.5–16 yr), and the other 14 normals had no contact with lupus material. The study was approved by the institution's human subjects committee and informed consents were obtained from all of the subjects who entered the study. All patients were studied twice, when their disease was active and again during clinical remission. Patients were considered to have active disease if organ-specific clinical symptoms plus at least two of the following laboratory criteria were present: (a) erythrocyte sedimentation rate > 25 mm/h; (b) total hemolytic complement CH₅₀ < 120 U; (c) DNA antibodies > 14% binding. Patients were considered to have inactive disease if no organ-specific clinical symptoms or signs could be elicited and if the laboratory criteria—erythrocyte sedimentation rate, CH₅₀, DNA antibodies—were within the normal range. None of the patients was on cytotoxic drugs. Prednisone dosage received by patients during active disease ranged from 5 to 6 mg/d (mean, 32.5 mg), and during inactive disease, from 0 to 40 mg/d (mean, 25 mg/d).

Serum complement determination (CH₅₀ assay) was done by a standard technique. The binding of sera to native DNA was studied by the Millipore filter radioimmunoassay (Millipore Corp., Bedford, Mass.) using human KB cell line [³H]DNA (Electro-Nucleonics, Inc., Fairfield, N. J.) (14).

Adsorption of anti-DNA antibody on DNA-cellulose columns. Calf thymus DNA-cellulose (Worthington Biochemical Corp., Freehold, N. J.) was suspended in buffer (0.01 M Tris-HCl, 0.001 M EDTA, pH 7.4), and packed in columns (K9/15 columns, Pharmacia Fine Chemicals, Uppsala, Sweden). For each 2 g of DNA-cellulose (containing 18 mg DNA), 10 ml of serum was allowed to pass through the column at 4°C at a rate of 2 drops/min. The effluents were passed again through the DNA-cellulose columns to insure complete removal of the anti-DNA antibody. Sera treated in this manner did not contain any detectable anti-DNA antibody (0% binding) when tested by radioimmunoassay (14). Cellulose columns to which no DNA was coupled were incapable of depleting anti-DNA antibody.

Treatment of DNA with immobilized DNase. 6 or 60 U of DNase-Sepharose conjugate (immobilized deoxyribonuclease, Worthington Biochemical Corp.), suspended in 1.0 ml,

was incubated with 10 μg [³H]DNA for 60 min at 37°C. The tubes were centrifuged at 720 g for 20 min, and 0.5 ml of the supernate was then dialyzed overnight against Tris-buffer saline. The DNA treated in this manner failed to bind to serum containing DNA antibodies. Thus, in a typical experiment, serum from an active lupus patient with 67% binding capacity (17,279 counts/min) to the undigested [³H]DNA failed to bind to the DNase-treated [³H]DNA (<1% binding). 6 U of DNase-Sepharose conjugate was as efficient as 60 U. Therefore, in all the experiments reported in this paper 6 U of immobilized DNase was used for the digestion of 1.0 ml of serum.

Suppression of anti-DNA binding to [³H]DNA by blocking sera or immunoglobulin fragments and testing of precipitate formation by Clq-binding assay. All sera to be tested for the presence of anti-anti-DNA antibody (antiidiotypic or blocking antibodies) were depleted of anti-DNA antibody by passage twice through DNA-cellulose columns and then treated with 6 U of DNase-Sepharose to digest DNA. In preliminary experiments, lupus sera with 90% DNA-binding capacity or with 10 μg DNA/ml could be completely depleted by this treatment. None of the blocking sera used in these experiments had DNA-binding capacity > 90% or DNA > 10 μg/ml. Adequacy of depletion was confirmed by the failure to detect anti-DNA antibody by radioimmunoassay (14) and of DNA by chromatography (15). The anti-DNA depleted and DNase-treated sera (blocking sera) were assayed for their capacity to inhibit the binding of [³H]DNA to sera from active lupus patients (target sera). For the blocking assay 100 μl containing 1 nmol of the blocking material IgG or its various fragments was incubated with 100 μl of a target serum (containing 1 nmol IgG) at 37°C for 1 h and then for 16 h at 4°C. The mixtures were centrifuged at 1,000 g for 30 min; 100 μl of the supernate was collected and tested in the standard DNA-binding assay (14). The remaining 100 μl, designated the precipitate fraction, was tested in a conventional Clq binding assay (16).

The percent suppression of DNA binding was calculated from the formula:

$$\left(1 - \frac{\text{DNA binding of mixtures of target and blocking sera}}{\text{DNA binding of target sera alone}}\right) \times 100.$$

Depletion of various Ig classes. Depletion of serum IgG, IgM, or IgA was performed by standard techniques as described earlier (17). Adequacy of depletion was confirmed by immunoelectrophoresis and by immunodiffusion.

Preparation of IgG, F(ab')₂, and Fc fragments. IgG proteins were isolated from serum by affinity chromatography on Protein A-Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Sweden). F(ab')₂ fragments produced by pepsin digestion of IgG proteins were separated from Fc-containing materials by passing over a column of Protein A-Sepharose 4B (18). Fab and Fc fragments, which were produced by papain digestion of IgG proteins, were separated also by Protein A-Sepharose 4B chromatography (18). These IgG fragments were separately passed through a column of Sephadex G-150 to ensure the removal of undigested IgG proteins. IgG and its enzymatic cleavage fragments thus prepared were immunologically pure and distinct when examined by immunoelectrophoresis.

Preparation of F(ab')₂ fragments from active lupus sera. To ensure that the blocking activity of the antiidiotypic antibody is directed towards the binding sites of anti-DNA antibody, we prepared F(ab')₂ fragments from IgG isolated from active lupus sera. The isolation of IgG proteins on Protein A-Sepharose 4B and the preparation of F(ab')₂ fragments by pepsin digestion were as described above.

Preparation of normal gammaglobulin immunoadsorbents. To ensure the specificity of the antiidiotypic antibody, we attempted to deplete its blocking activity by passing it through normal gammaglobulin immunoadsorbent columns. Gammaglobulins were isolated from five different normal sera by 33% ammonium sulfate precipitation. The precipitate was washed, dialyzed, redissolved, and covalently coupled to CNBr-activated Sepharose 4B according to the method described by March et al. (19). Such affinity chromatography media were denoted as gammaglobulin immunoadsorbents. Aliquots of one antiidiotypic serum—prepared from inactive lupus serum as described above—were allowed to pass through the five different immunoadsorbents. The blocking activity of the antiidiotypic serum was tested before and after its passage through the various immunoadsorbents.

Hemagglutination assay. To test for specificity of the autoantiidiotypic antibody, serum from a normal donor who had recently been boosted with tetanus toxoid was used as the target serum. Antitetanus antibody was assayed by the standard passive hemagglutination assay using chromium chloride to coat sheep erythrocytes with tetanus toxoid (20).

Statistical analysis. The paired *t* test was used to compare suppression of target sera in the presence or absence of blocking sera. For comparison of percent suppression with Clq binding, the Spearman rank correlation coefficient was calculated (21).

RESULTS

Blocking of anti-DNA binding. Autologous sera from lupus patients with inactive disease ($n = 19$) were found to suppress the binding of [^3H]DNA to the target lupus sera ($P < 0.01$) (Fig. 1, Table I). Blocking sera from active unrelated ($n = 9$), from active autologous ($n = 19$), or from inactive unrelated ($n = 9$) lupus patients were not capable of suppression. Human serum albumin at a similar protein concentration and processed similarly to the various blocking sera was also incapable of suppression (Fig. 1). The mean suppression value of the 19 various normal sera tested, when pooled together, was not significantly different from the percent DNA binding of the target lupus sera




FIGURE 1 Suppression of anti-DNA binding to [^3H]DNA by various sera. Results are the means \pm SD. 19 sera were tested for each of the normals, SLE active autologous, and SLE inactive autologous groups. Nine sera were tested for each of SLE active unrelated and SLE inactive unrelated groups.

by themselves ($P = 0.2$) (Fig. 1, Table I). However, normal sera from donors who had contact with lupus patients and lupus blood components had significant suppressive activity on the target active lupus sera ($P < 0.02$) (Tables I and II). Sera from normal donors who had no contact with lupus material did not suppress ($P > 0.5$) (Table II).

Clq binding correlated with suppression of DNA binding. Precipitate fractions obtained from incubating $\text{F}(\text{ab}')_2$ fragments with the corresponding autologous target sera were tested for their ability to bind ^{125}I -Clq by radioimmunoassay. The upper limits of the 95% confidence intervals for individual values of fragments from active lupus sera are shown with dotted lines parallel to each axis (25% for suppression, 8% for Clq binding) (Fig. 2). Low Clq binding values (3–7%) occurred with sera and fragments from active lupus patients; higher Clq binding values (8–34%) occurred with those from patients with inactive lupus (Fig. 2). When samples from patients with active and inactive disease were considered together, percent suppression correlated significantly with Clq binding (Spearman's $\rho = 0.92$, $P < 0.01$).

Effects of immunoglobulin depletion of the blocking sera. In the five experiments performed on five different sera, depletion of IgG eliminated the suppressive capacity of the autologous inactive lupus serum (Fig. 3). Depletion of IgM or of IgA failed to do so ($P < 0.01$).

Failure of depletion of the blocking activity by adsorption on normal human gammaglobulin. To avoid artefacts upon IgG depletion of blocking sera by immunoadsorbents, it is shown in Table III that normal gammaglobulin immunoadsorbents from five different donors failed to deplete the blocking activity of the lupus serum.

Effects of IgG fragments on DNA binding. In the nine sera that were processed and tested, $\text{F}(\text{ab}')_2$ fragments and not Fc fragments of the inactive lupus sera were capable of suppressing the binding of anti-DNA antibody to [^3H]DNA ($P < 0.001$) (Fig. 4). Fab fragments ($P < 0.02$), whole serum ($P < 0.01$), and globulin fractions ($P < 0.01$) were also inhibitory.

Effects of the blocking IgG on binding of $\text{F}(\text{ab}')_2$ fragments of the active lupus IgG to [^3H]DNA. To ensure that the blocking activity of the inactive autologous IgG is directed towards the binding sites of the anti-DNA antibody, we have prepared $\text{F}(\text{ab}')_2$ fragments from IgG of five different active lupus sera. It could be seen from Table IV that the blocking IgG inhibited the binding of the $\text{F}(\text{ab}')_2$ fragments to [^3H]DNA. Fc fragments prepared from the same active lupus sera failed to bind to [^3H]DNA in the absence or presence of the blocking IgG (not shown in Table IV).

Effect of IgG fragments on tetanus toxoid binding. Whole serum, globulin fraction, or the various IgG frag-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.